Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND) Meeting Abstract
| Authors: | Badar, T.; Atallah, E. L.; Saliba, A. N.; Shallis, R. M.; Stahl, M. F.; Bewersdorf, J. P.; Correia, G. S. D.; Patel, A. A.; Abaza, Y.; Murthy, G. S. G.; Duvall, A. S.; Burkart, M.; Palmisiano, N.; Bradshaw, D.; Kota, V. K.; Dinner, S.; Goldberg, A. D.; Litzow, M. R. |
| Abstract Title: | Clinical outcomes of patients with TP53-mutated AML after first relapse or with primary refractory disease: Results from consortium on myeloid malignancies and neoplastic diseases (COMMAND) |
| Meeting Title: | 64th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 140 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Dec 10-13 |
| Meeting Location: | New Orleans, LA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2022-11-15 |
| Start Page: | 6058 |
| End Page: | 6060 |
| Language: | English |
| ACCESSION: | WOS:000893223206035 |
| DOI: | 10.1182/blood-2022-163795 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
